ERBB2 and breast cancer: Gene expression profiling has revealed four main intrinsic molecular subtypes of breast cancer that show substantial differences in phenotypic presentation, prognosis, treatment response, and outcome [1–5]: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple negative (TN) [6–8].